
- Telehealth Visits
- Insurance plan information

Annemieke van Zante, MD, PhD
Anatomic Pathology • Cytopathology- Telehealth Visits
- Insurance plan information



Annemieke van Zante, MD, PhD
Anatomic Pathology • Cytopathology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Annemieke van Zante is a pathologist who performs and analyzes fine needle aspiration biopsies (in which a needle is inserted into a lump or other abnormal tissue to take a sample of cells). She has a particular interest in head and neck disease processes, reviewing specimens and providing consultations for head and neck cancer.
In her research, van Zante focuses on certain molecular processes involved in regulating cancer cell proliferation.
Van Zante earned her medical degree and doctorate in the UCSF Medical Scientist Training Program. She completed a residency at UCSF in anatomic pathology, the study of disease both microscopically and by looking at entire bodies and organ systems. She also completed fellowships in surgical pathology and cytopathology, the study of abnormalities within cells, at UCSF.
Education & training
Board certification
- Cytopathology, American Board of Pathology
- Anatomic Pathology, American Board of Pathology
Fellowship
- Cytopathology, UCSF Graduate Medical Education
- Surgical Pathology, UCSF Graduate Medical Education
Residency
- Anatomic/Clinical Pathology, UCSF Graduate Medical Education
Degree
- MD, UCSF School of Medicine
My expertise
Specialties
- Anatomic Pathology
- Cytopathology
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%221063%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221063%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.